ARS Pharmaceuticals, Inc. Operating Expenses
ARS Pharmaceuticals, Inc. (SPRY) reported Operating Expenses of $95.12 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingExpenses · last filed 2026-08-13
- ARS Pharmaceuticals, Inc. operating expenses for the quarter ending 2026-06-30 was $95.12M, a 50.20% increase year-over-year.
- ARS Pharmaceuticals, Inc. operating expenses for the quarter ending 2026-03-31 was $82.83M, a 83.45% increase year-over-year.
- ARS Pharmaceuticals, Inc. operating expenses for the quarter ending 2025-12-31 was $69.55M, a 76.60% increase year-over-year.
- ARS Pharmaceuticals, Inc. operating expenses for the quarter ending 2025-09-30 was $85.69M, a 259.81% increase year-over-year.
- ARS Pharmaceuticals, Inc. operating expenses for fiscal 2025 was $263.73M, a 185.94% increase from fiscal 2024.
- ARS Pharmaceuticals, Inc. operating expenses for fiscal 2024 was $92.23M, a 36.54% increase from fiscal 2023.
- ARS Pharmaceuticals, Inc. operating expenses for fiscal 2023 was $67.55M, a 83.40% increase from fiscal 2022.
- ARS Pharmaceuticals, Inc. operating expenses for fiscal 2022 was $36.83M, a 47.56% increase from fiscal 2021.
| Period end | Operating Expenses 3 month | Operating Expenses 3 month as first filed | Operating Expenses 6 month | Operating Expenses 6 month as first filed | Operating Expenses 9 month | Operating Expenses 9 month as first filed | Operating Expenses 12 month | Operating Expenses 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $95.12M 10-Q · filed 2026-08-13 | $177.95M 10-Q · filed 2026-08-13 | $247.50M derived: sum of 3 quarters · filed 2026-08-13 | $333.19M derived: sum of 4 quarters · filed 2026-08-13 | ||||
| 2026-03-31 | $82.83M 10-Q · filed 2026-05-15 | $152.38M derived: sum of 2 quarters · filed 2026-05-15 | $238.07M derived: sum of 3 quarters · filed 2026-05-15 | $301.40M derived: sum of 4 quarters · filed 2026-08-13 | ||||
| 2025-12-31 | $69.55M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $155.25M derived: sum of 2 quarters · filed 2026-03-09 | $218.58M derived: sum of 3 quarters · filed 2026-08-13 | $263.73M 10-K · filed 2026-03-09 | ||||
| 2025-09-30 | $85.69M 10-Q · filed 2025-11-10 | $149.02M derived: sum of 2 quarters · filed 2026-08-13 | $194.17M 10-Q · filed 2025-11-10 | $233.56M derived: sum of 4 quarters · filed 2026-08-13 | ||||
| 2025-06-30 | $63.33M 10-Q · filed 2026-08-13 | $108.48M 10-Q · filed 2026-08-13 | $147.87M derived: sum of 3 quarters · filed 2026-08-13 | $171.68M derived: sum of 4 quarters · filed 2026-08-13 | ||||
| 2025-03-31 | $45.15M 10-Q · filed 2026-05-15 | $84.53M derived: sum of 2 quarters · filed 2026-05-15 | $108.35M derived: sum of 3 quarters · filed 2026-05-15 | $124.19M derived: sum of 4 quarters · filed 2026-05-15 | ||||
| 2024-12-31 | $39.38M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $63.20M derived: sum of 2 quarters · filed 2026-03-09 | $79.04M derived: sum of 3 quarters · filed 2026-03-09 | $92.23M 10-K · filed 2026-03-09 | ||||
| 2024-09-30 | $23.82M 10-Q · filed 2025-11-10 | $39.66M derived: sum of 2 quarters · filed 2025-11-10 | $52.85M 10-Q · filed 2025-11-10 | $63.07M derived: sum of 4 quarters · filed 2025-11-10 | ||||
| 2024-06-30 | $15.84M 10-Q · filed 2025-08-13 | $29.03M 10-Q · filed 2025-08-13 | $39.26M derived: sum of 3 quarters · filed 2025-08-13 | $57.24M derived: sum of 4 quarters · filed 2025-08-13 | ||||
| 2024-03-31 | $13.19M 10-Q · filed 2025-05-14 | $23.42M derived: sum of 2 quarters · filed 2025-05-14 | $41.40M derived: sum of 3 quarters · filed 2025-05-14 | $62.01M derived: sum of 4 quarters · filed 2025-05-14 | ||||
| 2023-12-31 | $10.23M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-20 | $28.20M derived: sum of 2 quarters · filed 2025-03-20 | $48.82M derived: sum of 3 quarters · filed 2025-03-20 | $67.55M 10-K · filed 2025-03-20 | ||||
| 2023-09-30 | $17.98M 10-Q · filed 2024-11-13 | $38.59M derived: sum of 2 quarters · filed 2024-11-13 | $57.32M 10-Q · filed 2024-11-13 | $72.77M derived: sum of 4 quarters · filed 2024-11-13 | ||||
| 2023-06-30 | $20.61M 10-Q · filed 2024-08-06 | $39.35M 10-Q · filed 2024-08-06 | $54.79M derived: sum of 3 quarters · filed 2024-08-06 | $61.61M derived: sum of 4 quarters · filed 2024-08-06 | ||||
| 2023-03-31 | $18.73M 10-Q · filed 2024-05-09 | $34.18M derived: sum of 2 quarters · filed 2024-05-09 | $40.99M derived: sum of 3 quarters · filed 2024-05-09 | $47.80M derived: sum of 4 quarters · filed 2024-05-09 | ||||
| 2022-12-31 | $15.44M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-21 | $22.26M derived: sum of 2 quarters · filed 2024-03-21 | $29.07M derived: sum of 3 quarters · filed 2024-03-21 | $36.83M 10-K · filed 2024-03-21 | ||||
| 2022-09-30 | $6.82M 10-Q · filed 2023-11-09 | $18.94M 10-Q · filed 2022-11-02 | $13.63M derived: sum of 2 quarters · filed 2023-11-09 | $21.39M 10-Q · filed 2023-11-09 | $63.44M 10-Q · filed 2022-11-02 | -$19.73M derived: sum of 4 quarters · filed 2023-11-09 | ||
| 2022-06-30 | $6.81M 10-Q · filed 2023-08-10 | $19.80M 10-Q · filed 2022-08-11 | $14.57M 10-Q · filed 2023-08-10 | $44.50M 10-Q · filed 2022-08-11 | -$26.55M derived: sum of 3 quarters · filed 2023-08-10 | -$3.87M derived: sum of 4 quarters · filed 2023-08-10 | ||
| 2022-03-31 | $7.76M 10-Q · filed 2023-05-15 | $24.70M 10-Q · filed 2022-05-12 | -$33.35M derived: sum of 2 quarters · filed 2023-05-15 | -$10.67M derived: sum of 3 quarters · filed 2023-05-15 | $13.84M derived: sum of 4 quarters · filed 2023-05-15 | |||
| 2021-12-31 | -$41.12M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-23 | -$18.44M derived: sum of 2 quarters · filed 2023-03-23 | $6.08M derived: sum of 3 quarters · filed 2023-03-23 | $24.96M 10-K · filed 2023-03-23 | $89.58M 10-K · filed 2022-03-31 | |||
| 2021-09-30 | $22.68M 10-Q · filed 2022-11-02 | $47.19M derived: sum of 2 quarters · filed 2022-11-02 | $66.08M 10-Q · filed 2022-11-02 | $79.18M derived: sum of 4 quarters · filed 2022-11-02 | ||||
| 2021-06-30 | $24.51M 10-Q · filed 2022-08-11 | $43.40M 10-Q · filed 2022-08-11 | $56.50M derived: sum of 3 quarters · filed 2022-08-11 | $64.61M derived: sum of 4 quarters · filed 2022-08-11 | ||||
| 2021-03-31 | $18.89M 10-Q · filed 2022-05-12 | $31.99M derived: sum of 2 quarters · filed 2022-05-12 | $40.10M derived: sum of 3 quarters · filed 2022-05-12 | $46.56M derived: sum of 4 quarters · filed 2022-05-12 | ||||
| 2020-12-31 | $13.10M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-31 | $21.21M derived: sum of 2 quarters · filed 2022-03-31 | $27.68M derived: sum of 3 quarters · filed 2022-03-31 | $32.92M 10-K · filed 2022-03-31 | ||||
| 2020-09-30 | $8.11M 10-Q · filed 2021-11-10 | $14.57M derived: sum of 2 quarters · filed 2021-11-10 | $19.82M 10-Q · filed 2021-11-10 | |||||
| 2020-06-30 | $6.46M 10-Q · filed 2021-08-12 | $11.71M 10-Q · filed 2021-08-12 | ||||||
| 2020-03-31 | $5.24M 10-Q · filed 2021-05-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 |